- $NOVO B (+1,47 %) reported a better-than-expected increase in net profit, but lowered its full-year sales growth forecast due to weaker sales of its blockbuster weight-loss drug, #wegovy.
- Sales of the popular obesity drug Wegovy amounted to 17.36 billion Danish kroner in the reporting period, slightly below the 18.51 billion Danish kroner expected by analysts.
- For 2025, the company now expects sales growth of 13% to 21% at constant exchange rates, which is below the previously forecast range of 16% to 24%.
Source: https://www.cnbc.com/amp/2025/05/07/novo-nordisk-nvo-earnings-q1-2025.html
